Clinical Trials Needed For Adolescents, Young Adults
Medical research has made great progress in preventing, detecting and treating cancer over the past 25 years, but the benefits of that success do not extend to adolescents and young adults.
|
Parents Don't Want Their Child To Participate In Medical Research
National Poll on Children's Health finds many parents willing to let children take part in medical research if risk of harm is minimal.
|
Velcura Therapeutics Trial Of Bone Disease Therapy Is Successful
Velcura Therapeutics announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis and other bone diseases.
|
R1626 - Hepatitis C Polymerase Inhibitor Demonstrated Improvement In A Study
Roche's investigational therapy for chronic hepatitis C virus infection, R1626, has shown a significant end-of-treatment response rate when given in combination with PEGASYS and COPEGUS.
|
Xibrom Combination Therapy With Lucentis Successful
Study that was designed to evaluate the adjuvant use of Xibrom 0.09% in Lucentis treatment of choroidal neovascularization secondary to age-related macular degeneration showed promising results.
|
Artificial blood linked to increased deaths, heart attacks
Developing blood substitude is a great medical advance, but a new study raises some serious concerns about the rush to bring these artificial blood substitutes to the market.
|
Studies Showed Higher SVR For PEGASYS Plus Ribavirin Successful In Treating Hepatitis C
Roche's three studies indicate that chronic hepatitis C patients who received PEGASYS plus ribavirin had a greater chance of achieving a sustained virological response than patients on peginterferon alfa-2b.
|
Micromet Initiates Trial For Solid Tumor Treatment
Micromet starts phase 1 clinical trial with its BiTE antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.
|
PTC Therapeutics Initiates Trial Of PTC124 In Muscular Dystrophy
PTC Therapeutics initiates an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation.
|
MMC Completes Studies For Integrated Hematology, Automated Diabetes Testing Solution
Sysmex America announced the successful completion of Mercy Medical Center's (Canton, OH) beta studies for its integrated hematology and A1C automation solution.
|
Elusys' Anthim Improves Survival Of Animals Treated After Active Anthrax Infection
Elusys Therapeutics announced pivotal animal efficacy results of Anthim, a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.
|
Data Shows Potential Treatment For Oral Mucositis Models
Nuvelo announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 in chemotherapy or radiation-induced oral mucositis models.
|
Mipomersen Is Well Tolerated, Maintains Activity In FH Patients
Isis Pharmaceuticals announced additional results from its ongoing Phase 2 open-label extension study of mipomersen in patients with familial hypercholesterolemia.
|
Napo Announces Successful Results In Study Of Crofelemer In Acute Adult Infectious Diarrhea
Napo Pharmaceuticals announces positive results of a successfully completed Phase 2 trial for CRO-ID conducted by Glenmark Pharmaceuticals.
|
Making Antibiotics From Alligator Blood
Researchers are on their way of developing new antibiotics from alligator blood that can even beat even drug-resistant superbugs.
|
Researcher Makes Gains In Finding Treatments
Leading RSV investigator Dr. John DeVincenzo has taken another step toward finding effective treatment for the disease that causes bronchiolitis and pneumonia.
|
Spectral's EAA Used In Study For Sepsis Anti-Endotoxin Therapy
Spectral Diagnostics's Endotoxin Activity Assay will be used to measure endotoxin levels during the enrolment of patients in a Phase III sub study, part of a multinational clinical trial evaluating the safety and effectiveness of a treatment for severe sepsis.
|
Cystic Fibrosis Trial In Children Returns Positive Data
Pharmaxis' Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product rhDNase.
|
Knowing Doctor's Financial Interests Doesn't Deter Clinical Trial Participants
A patient's willingness to participate in a clinical trial may be unaffected by the disclosure of a researcher's financial interests in the study, unless the amount of money a researcher stands to earn depends on the results of the trial.
|
Synosia Starts Phase II Efficacy Trial For Rufinamide
The trial is an eight-week, double-blind, placebo-controlled, exploratory study being conducted in 20 sites in the United States.
|
IntelliPharmaCeutics Completes Trial For Abuse, Alcohol Resistant Sustained Release Oxycodone
IntelliPharmaCeutics announces significant results from a recently completed pilot clinical trial for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone formulation by its operating company IntelliPharmaCeutics.
|
Aeterna Zentaris Initiates Trial Of Cetrorelix For Benign Prostatic Hyperplasia
Aeterna Zentaris reported dosing has commenced with its flagship product candidate, cetrorelix in the second efficacy study of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate.
|
Nventa Announces Positive Data From Cervical Dysplasia Trial
Nventa Biopharmaceuticals Corporation announced interim immunological data from the first two cohorts of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer.
|
NPS Reports Successful GATTEX Extension Study
NPS Pharmaceuticals reported positive top-line results from a 28-week blinded Phase 3-extension study of GATTEX for short bowel syndrome patients who are dependent upon parenteral nutrition.
|
Genetic tests for common diseases: new insights, old concern
Better regulation is urgently needed for genetic tests, particularly those marketed directly to the public.
|
Labopharm Reports Positive Results For Once-Daily Trazodone Study
Labopharm's Phase III clinical trial for its once-daily formulation of the antidepressant trazodone achieved statistical significance for the primary efficacy endpoint.
|
Molecular Therapy Succeeds In Preventing Craniofacial Birth Defect In Mice
A new gene-based technique has successfully prevented a rare craniofacial birth defect in mice and holds promise to help children with the same disorder.
|
NHLBI Changes Intensive Blood Sugar Treatment Strategy In Clinical Trial
NHLBI has stopped one treatment within a clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns.
|
Plan Expedites Alternatives To Animal Testing
New drugs are tested on animals to predict toxicity on humans, but scientists are working to promote the development and validation of alternative test methods.
|
Researchers To Identify, Generate Molecules For Microbicide Research
Researchers have used a technique called phage display to identify and generate molecules for use in microbicide research and development.
|
Epistem, AstraZeneca Complete Plucked Hair Biomarker Study For Oncology Drug Development
Epistem had successfully completed a preliminary study with AstraZeneca for the use of its proprietary, minimally invasive plucked human hair biomarker technology to help steer oncology drug development.
|
Alexza Initiates AZ-007 Clinical Trial
Alexza Pharmaceuticals has initiated a Phase 1 clinical trial with AZ-007 (Staccato zaleplon).
|
Mifamurtide Study Demonstrates Improved Survival
IDM Pharma's Phase 3 mifamurtide clinical trial is the largest study completed in this disease was a NCI funded cooperative group study conducted by COG.
|
MUSC Spin-Off Company To Test Regenerative Wound Healing Gel
First-String Research has begun the human clinical trial process for its unique, wound-healing peptide gel.
|
Ustekinumab Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
Therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year.
|
TargeGen Initiates Trial Of JAK2 Inhibitor TG101348 In Myeloproliferative Disease Patients
TargeGen has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.
|
Data Show Transfusion Patterns In Chemotherapy-Induced Anemia Patients
Analyses reported a significantly lower proportion of patients receiving transfusions when ESAs treatment was initiated at hemoglobin levels between 10 to 11 grams per deciliter of blood compared with patients having Hb levels less than 10 g/dL prior to ESA treatment.
|
Phosphagenics Reports Positive Cholesterol Results From APA-01, Atorvastatin Combination
Combination of APA- 01 product candidate and the statin atorvastatin significantly reduced serum lipids and inflammatory proteins involved in the development of atherosclerosis.
|
Kiadis Pharma Successfully Completes Rhitol Clinical Study
Kiadis Pharma has successfully finalized its Rhitol Phase II clinical trial with the last patient completing its six month treatment cycle.
|
NPS Provides Update On GATTEX Clinical Development In Short Bowel Syndrome
NPS Pharmaceuticals to begin a confirmatory Phase 3 clinical study to evaluate GATTEX in patients with short bowel syndrome.
|
